In the last month, there has been a change for the worse, and there is still no good news. On May 17, Evofem Biosciences lost 30% and fell below $1. The stock has been floating at $0.8 for two weeks and now it stands at $1.03.
Recently, at the Jefferies Virtual Healthcare Conference 2021, the company’s CEO, Saundra Pelletier, presented new events. The company, developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, announced new discoveries.
Evofem provided information about EVO100, medicine for gonorrhea and chlamydia; released Phexxi, a pregnancy-preventing contraceptive gel, approved by FDA and much more. All this news may help the company to recover from the loss in recent days.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.